CareDx (NASDAQ:CDNA) Announces Quarterly Earnings Results

CareDx (NASDAQ:CDNA) posted its earnings results on Tuesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.12), FiscalAI reports. The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $102.76 million. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.33%. CareDx’s quarterly revenue was up 25.2% on a year-over-year basis. During the same quarter last year, the business earned $0.18 earnings per share.

Here are the key takeaways from CareDx’s conference call:

• Q4 revenue of $108.4 million (+25% y/y) and full‑year revenue of $379.8 million (+14% y/y), testing volume up 17% in Q4, ~69% non‑GAAP gross margin, positive adjusted EBITDA (Q4 $6.5M, FY $31.7M), roughly $201M cash and no debt, and ~$88M of share repurchases in 2025.
• Management highlighted multiple product launches and pipeline progress, including AlloSure Heart (pediatrics), AlloSure Plus, HistoMap Kidney and pivotal AlloHeme (ACROBAT) data that detected relapse a median 41 days earlier with 85% sensitivity/92% specificity and a planned commercial rollout in early 2027 targeting payer coverage in 2028.
• A draft Medicare Local Coverage Determination (LCD) could reduce annual revenue by about $15M; the company baked a conservative $7.5M (half‑year) hit into 2026 guidance and also expects a PLA code reimbursement cut that pushes blended revenue per test into the low $1,400s.
• Operations and cash collection improved materially—DSO improved from 71 to 41 days and 2025 cash collections rose ~32% to $405.6M—and the company is investing ~$10M in Epic Aura/Epic Enterprise LIMS integrations, which management says is already reducing login issues (~40%) and should improve order quality, billing and long‑term volume growth.

CareDx Trading Down 1.7%

Shares of NASDAQ:CDNA opened at $18.15 on Thursday. The firm has a market capitalization of $933.40 million, a PE ratio of -45.34 and a beta of 2.51. CareDx has a 1-year low of $10.96 and a 1-year high of $22.95. The business’s 50 day moving average is $19.66 and its 200-day moving average is $16.75.

Insider Buying and Selling

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the sale, the chief executive officer owned 597,405 shares of the company’s stock, valued at $12,641,089.80. The trade was a 3.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 29,636 shares of company stock valued at $625,949 over the last three months. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CDNA. Deerfield Management Company L.P. acquired a new position in shares of CareDx in the 3rd quarter worth approximately $31,857,000. Boston Partners lifted its holdings in shares of CareDx by 2,776.5% during the fourth quarter. Boston Partners now owns 901,929 shares of the company’s stock valued at $16,994,000 after acquiring an additional 870,574 shares during the period. Millennium Management LLC boosted its stake in shares of CareDx by 504.0% in the 3rd quarter. Millennium Management LLC now owns 413,689 shares of the company’s stock valued at $6,015,000 after purchasing an additional 345,197 shares in the last quarter. Palo Alto Investors LP bought a new stake in shares of CareDx in the 3rd quarter worth about $4,598,000. Finally, Janus Henderson Group PLC increased its position in shares of CareDx by 1,213.1% during the 4th quarter. Janus Henderson Group PLC now owns 287,561 shares of the company’s stock worth $5,418,000 after purchasing an additional 265,661 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a report on Monday, December 29th. Craig Hallum lowered shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price on the stock. in a research note on Tuesday, January 6th. Zacks Research raised shares of CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. BTIG Research raised their price target on CareDx from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.33.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.